Pinealon
EDR Peptide (L-Glutamyl-L-Aspartyl-L-Arginine)
Human data is very limited. Most evidence comes from case reports or observational studies.
A synthetic short peptide from pineal gland research that has shown brain-protective effects in laboratory and animal studies by reducing damage from harmful molecules and preventing brain cell death. Limited human-relevant evidence exists alongside multiple laboratory studies.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Pinealon has a very low reported side effect profile across both the Russian clinical literature and community reports. Accessible peer-reviewed abstracts did not provide systematic adverse-event tables. The human study of 32 patients (PMID 26390612) noted prooxidant activity by chemiluminescence and decreased CD34+ hematopoietic cells, which warrant monitoring but did not produce clinical adverse events in that study. The study used combined Pinealon + Vesugen so attribution to Pinealon alone is uncertain. Community reports in online communities describe minimal side effects, typically limited to mild fatigue if dosed during daytime. In vitro, EDR did not demonstrate direct antioxidant activity but restricted lipid peroxidation by modifying lipoprotein structure, and elevated intracellular ROS while simultaneously decreasing cell death (PMID 18546826), suggesting a complex hormetic mechanism. No systematic safety monitoring has been conducted.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-16]